Exelixis
EXEL
#1826
Rank
HK$91.41 B
Marketcap
HK$340.96
Share price
-1.20%
Change (1 day)
24.96%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): HK$18.56

According to Exelixis's latest financial reports the company's current EPS (TTM) is HK$18.60. In 2023 the company made an earnings per share (EPS) of HK$5.11 an increase over its 2022 EPS that were of HK$4.45.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)HK$18.56
2023HK$5.1114.61%
2022HK$4.45-22.97%
2021HK$5.78100%
2020HK$2.89-65.09%
2019HK$8.28-53.91%
2018HK$17.97333.96%
2017HK$4.14-260.61%
2016-HK$2.58-58.75%
2015-HK$6.25-42.45%
2014-HK$10.865.3%
2013-HK$10.32

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
HK$87.04 367.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
HK$10.63-42.86%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
HK$111.99 502.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
HK$16.14-13.23%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
HK$57.10 207.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
HK$23.21 24.79%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
HK$29.45 58.32%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-HK$28.68-254.20%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-HK$6.56-135.29%๐Ÿ‡บ๐Ÿ‡ธ USA